Agenus (AGEN) has released an update.
Agenus Inc. reached a significant milestone in its partnership with Bristol Myers Squibb by initiating the phase 2 dose expansion of the CA115-001 clinical trial with BMS-986442, which led to a $25 million payment received by January 30, 2024.
For further insights into AGEN stock, check out TipRanks’ Stock Analysis page.
For a comprehensive understanding of the announcement, you can read the full document here.
